Abbott Laboratories (ABT) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is a modest beat or in-line print — consensus EPS of ~$1.28 sits comfortably within the $1.25–$1.31 guidance range, but the real swing factor is whether CGM returns to double-digit growth as management promised, and whether the Exact Sciences integration is tracking ahead of the $3B incremental revenue target.

Heading into Q2 2026, the bar for Abbott is calibrated but not easy: consensus EPS of $1.28 (Visible Alpha) sits at the midpoint of management's $1.25–$1.31 guidance range, leaving limited room for a meaningful upside surprise on the bottom line unless segment mix or FX cooperates. The most important variable is FreeStyle Libre / CGM — after a disappointing 7.5% growth in Q1 (dragged by an international tender delay and tough prior-year shelf-restocking comps), management explicitly guided for a return to double-digit growth in Q2, and consensus has moved to ~$2.10B; any shortfall here would be the primary negative catalyst. On the positive side, Electrophysiology is accelerating as Abbott broadens the launch of both Volt PFA (U.S.) and TactiFlex Duo (Europe), and Core Lab Diagnostics is expected to continue its sequential improvement as China VBP headwinds lap. The stock has been a notable underperformer since Q1 earnings — down ~6.5% vs. XLV Healthcare ETF up ~8% over the same period — reflecting lingering skepticism around Nutrition recovery, Exact Sciences integration drag, and the absence of a respiratory season tailwind in guidance. At ~22x forward P/E (vs. a 5-year average of ~25x and MedTech peers at ~45x), the valuation is not demanding, but the stock needs execution proof points to re-rate. The wildcard is Exact Sciences: any commentary suggesting Cologuard growth is tracking above the mid-teens pace seen in Q1, or that international cancer screening expansion is gaining traction faster than expected, could be the positive surprise that shifts sentiment.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a manageable bar — EPS and revenue estimates sit within guidance, but FreeStyle Libre is the biggest swing factor: a return to double-digit growth is already priced in, and any miss on CGM would likely dominate the stock reaction. Diagnostics consensus ($3.05B) is elevated due to the Exact Sciences addition and will be the second most-watched line.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. Q2 2026 consensus estimates as of latest available. Revenue elevated YoY in Diagnostics reflects full-quarter consolidation of Exact Sciences (acquired March 23, 2026; adds ~$3B incremental FY2026 revenue). FY2026 consensus total revenue: $50.0B.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Adj. EPS & FreeStyle Libre)

Pattern: Abbott has been a consistent EPS in-liner or modest beater over the last 8 quarters, with FreeStyle Libre the more volatile KPI — it has missed consensus in 2 of the last 3 quarters (Q1 2026 and Q4 2025), a notable shift from the prior trend of consistent beats. The Q2 2026 setup requires CGM to re-accelerate to double-digit growth to avoid a third consecutive miss on the franchise's most-watched line.

3. Guidance & Commentary Evolution

Key Takeaway: Management's tone since Q1 2026 earnings (April 16) has been constructively confident on the H2 acceleration thesis — CGM, EP, and Core Lab are all expected to inflect higher — but the Nutrition recovery is still early-stage and the Exact Sciences integration, while described as going "very well," adds near-term EPS dilution of ~$0.20 for FY2026.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimate revisions since Q1 2026 earnings have been largely stable to slightly negative — consensus EPS for Q2 2026 moved from ~$1.34 (pre-Q1 earnings) to $1.28 (current), reflecting the Exact Sciences dilution and softer-than-expected Q1 tone. Revenue estimates moved higher due to Exact Sciences consolidation, masking underlying organic growth concerns in Nutrition.

Source: Visible Alpha Consensus and Actuals Data. Pre-Q1 earnings baseline as of April 22, 2026 (one week post-Q1 print, after initial analyst revisions). Current consensus as of latest available (July 2026). The stability in EPS estimates reflects management's tight guidance range; the slight revenue trim reflects modest organic growth skepticism offset by Exact Sciences consolidation.

5. Stock Performance

Key Takeaway: ABT has been a significant underperformer since Q1 2026 earnings — down ~6.5% (indexed) vs. XLV Healthcare ETF up ~8% over the same period, a ~14.5 percentage point gap. The stock closed at $89.27 on July 15, 2026, well below the pre-earnings close of $101.56 (April 15), reflecting persistent investor skepticism around Nutrition recovery, Exact Sciences integration drag, and CGM growth moderation.

ABT vs. XLV Healthcare ETF — Indexed to 100 at Q1 2026 Earnings (Apr 16, 2026). Source: Stock Price Data.

Recent analyst actions: Raymond James cut PT from $130 to $115 (Outperform); Barclays trimmed from $144 to $143 (Overweight); Mizuho cut from $125 to $115 (Neutral); UBS cut from $158 to $135 (Buy); Bank of America cut from $120 to $102 (June 12); Evercore ISI cut from $120 to $112 (Outperform, July 6); Baird initiated at Outperform with $121 PT. The broad-based PT cuts reflect post-Q1 earnings reset, but the majority of analysts maintain constructive ratings, suggesting the bar is now lower heading into Q2.

6. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peer commentary from Q1 2026 earnings calls (reported April–June 2026) is broadly constructive for ABT's Q2 setup — ISRG and EW signal healthy procedure volumes and structural heart demand, DXCM's reaffirmed guidance and strong CGM growth support the CGM market thesis, and BSX's EP commentary (despite its own Q2 headwinds) validates the PFA catheter opportunity. The main caution: BSX flagged Q2 as its "toughest quarter" in EP due to tough comps, which could signal some market-level softness that ABT's Volt PFA launch must overcome.

DexCom (DXCM) — Q1 2026 Earnings (Apr 30, 2026) & Investor Day (May 14, 2026)

Relevance to ABT: Direct CGM market read-through for FreeStyle Libre.

• DXCM reported 15% revenue growth (12% organic) in Q1 2026, driven by strong global demand for CGM. The company reaffirmed its full-year revenue guidance of $5.16B–$5.25B (11%–13% growth) and raised its non-GAAP operating margin guidance to 23%–23.5%.
• Read-through for ABT: DXCM's strong Q1 and reaffirmed guidance confirm that the CGM market remains healthy and growing. ABT's Q1 CGM miss was company-specific (international tender delay, tough comps) rather than a market-level issue. This supports management's guidance for a return to double-digit CGM growth in Q2 2026.
• At its May 14 Investor Day, DXCM highlighted continued expansion in Type 2 non-insulin users and international market penetration — both key growth vectors that ABT has also cited as major long-term drivers for FreeStyle Libre.
• Caution: DXCM's strong performance sets a high bar for CGM market growth expectations. If ABT's CGM growth comes in below double digits again, the contrast with DXCM's 12% organic growth will be unfavorable.

Boston Scientific (BSX) — Q1 2026 Earnings (Apr 22, 2026)

Relevance to ABT: EP market dynamics, WATCHMAN/LAA, and broader MedTech demand.

• BSX reported 9.4% organic growth in Q1 2026 but reduced its full-year organic growth guidance to 6.5%–8% (from prior range) and guided Q2 organic growth of 5%–7%, calling Q2 its "toughest quarter of the year" due to challenging dollar sequential comps in EP and WATCHMAN.
• Read-through for ABT (EP): BSX's EP headwinds in Q2 are largely comp-driven (BSX had a very strong Q2 2025 in EP/WATCHMAN). ABT's EP business is in a different phase — it is in early launch mode for Volt PFA and TactiFlex Duo, so it is growing off a lower base. The PFA catheter market is expanding, and ABT is a new entrant gaining share, which should insulate it from the comp-driven headwinds BSX faces.
• BSX noted that Urology and Endoscopy also faced transient headwinds in Q2, but expected these to resolve in H2 2026. The overall MedTech market was described as structurally healthy.
• Caution: BSX's guidance cut is a reminder that even strong MedTech franchises can face quarterly volatility. ABT's Structural Heart segment (MitraClip, TAVR) faces similar competitive dynamics to BSX's structural heart portfolio.

Edwards Lifesciences (EW) — Q1 2026 Earnings (Apr 23, 2026)

Relevance to ABT: Structural heart / TAVR market demand and hospital procedure volumes.

• EW reported 12.7% sales growth in Q1 2026, "ahead of expectations," driven by broad-based growth across product groups. The company raised its full-year 2026 sales growth guidance to 9%–11% and TAVR growth guidance to 7%–9%.
• Read-through for ABT (Structural Heart): EW's strong TAVR performance and raised guidance signal that the structural heart market is healthy and procedure volumes are robust. This is a positive read-through for ABT's Structural Heart segment, which faced U.S. execution challenges and competitive pressure in mitral in Q1. A healthy market environment reduces the risk that ABT's Q1 Structural Heart weakness was market-driven rather than company-specific.
• EW's Q2 guidance of $1.66B–$1.74B in sales with adjusted EPS of $0.70–$0.76 implies continued strong momentum, which bodes well for the broader structural heart market in which ABT competes.

Intuitive Surgical (ISRG) — Q1 2026 Earnings (Apr 21, 2026)

Relevance to ABT: Hospital procedure volumes, capital spending environment, and broader surgical market health.

• ISRG reported 17% procedure growth and 23% revenue growth in Q1 2026, raising its full-year da Vinci procedure growth forecast to 13.5%–15.5%. The company noted 100 bps of tariff impact on gross margins but maintained a constructive outlook.
• Read-through for ABT: ISRG's strong procedure volumes confirm that hospital utilization and surgical demand remain robust — a positive backdrop for ABT's Medical Devices segment broadly. The hospital CapEx environment is described as steady, which supports ABT's Core Lab Diagnostics capital equipment sales.
• ISRG's tariff commentary (100 bps gross margin impact) is a watch item for ABT, which has global manufacturing and supply chains that could face similar cost pressures.

Stryker (SYK) — Q1 2026 Earnings (Apr 30, 2026)

Relevance to ABT: MedTech market demand, hospital CapEx, and orthopedic/surgical volumes.

• SYK's Q1 organic growth was only 2.4%, "meaningfully impacted" by a cyber incident. However, the company maintained its full-year guidance of 8%–9.5% organic growth and $14.90–$15.10 EPS, expecting to recover most lost Q1 sales throughout the rest of the year.
• Read-through for ABT: SYK's maintained guidance despite a significant operational disruption signals strong underlying demand fundamentals. The hospital CapEx environment was described as "steady" with an elevated capital order book — a positive for ABT's Core Lab Diagnostics capital equipment and Medical Devices segments.
• SYK noted "healthy" underlying demand across its businesses, consistent with the broader MedTech market narrative from ISRG and EW.

Medtronic (MDT) — Q4 FY2026 Earnings (Jun 3, 2026)

Relevance to ABT: Cardiac rhythm management, EP, and broader MedTech market; MDT's fiscal Q4 ended April 2026, covering the same calendar period as ABT's Q2 2026.

• MDT reported Q4 FY2026 organic growth of 6.6%, contributing to its strongest full-year top-line performance in 10 years (5.8% organic for FY2026). For FY2027, MDT guided 6.75%–7.25% organic revenue growth and adjusted EPS of $5.90–$6.00.
• Read-through for ABT: MDT's strong cardiac and EP performance validates the structural demand for electrophysiology products. MDT described the market as "structurally resilient" with "durable fundamentals" — a positive backdrop for ABT's EP acceleration thesis with Volt PFA and TactiFlex Duo.
• MDT's Q1 FY2027 guidance of 11.5%–12% organic growth (covering May–July 2026) signals continued strong MedTech market momentum heading into ABT's Q2 2026 reporting period.
• MDT's FY2027 guidance implies confidence in the broader healthcare market environment, which is constructive for ABT's diversified portfolio.

Becton Dickinson (BDX) — Q2 FY2026 Earnings (May 7, 2026)

Relevance to ABT: Diagnostics market, China dynamics, and hospital supply chain.

• BDX reported 2.6% FX-neutral growth in its fiscal Q2, with over 90% of its portfolio growing mid-single digits. Headwinds came from Alaris, vaccines, and China (collectively <10% of revenue). BDX reaffirmed its full-year revenue guidance (low single digits) and raised adjusted EPS guidance to $12.52–$12.72.
• Read-through for ABT (Diagnostics): BDX's China headwinds (VBP-related) are consistent with ABT's own China Core Lab experience, but BDX's commentary that these represent a small and contained portion of revenue is encouraging. ABT has guided for China Core Lab stabilization in 2026, and BDX's experience suggests the VBP cycle may be nearing its end for the broader diagnostics market.
• BDX's strong performance in the 90%+ of its portfolio growing mid-single digits confirms healthy underlying diagnostics demand ex-China, which is a positive read-through for ABT's Core Lab business.

Thermo Fisher Scientific (TMO) — Q1 2026 Earnings (Apr 23, 2026) & Investor Day (May 20, 2026)

Relevance to ABT: Life sciences / diagnostics market environment and biopharma customer spending.

• TMO reported Q1 2026 results and held an Investor Day in May 2026. TMO's commentary on biopharma customer spending and diagnostics market conditions provides context for ABT's Core Lab and Cancer Diagnostics (Exact Sciences) businesses.
• Read-through for ABT: TMO's Investor Day highlighted continued investment in diagnostics infrastructure and life sciences tools, consistent with ABT's thesis that the Core Lab diagnostics market is recovering and that cancer diagnostics (Cologuard, MRD testing) represents a large and underpenetrated opportunity.

Peer Read-Through Summary Table

7. Material News & Developments (Since Q1 2026 Earnings)

Key Takeaway: The most significant post-Q1 development is the Exact Sciences integration progress and the announcement of Q2 earnings on July 16 — no material negative news has emerged since the April 16 print, but the stock has continued to drift lower, suggesting the market is waiting for execution proof points rather than reacting to new negative catalysts.

• Q2 2026 Earnings Announcement (June 25, 2026): Abbott announced it will release Q2 2026 financial results on July 16, 2026, before market open, with a live webcast conference call at 8 a.m. CT / 9 a.m. ET.
• Infant Formula Derivative Suit Settlement (April 17, 2026): Abbott reached a preliminary settlement in infant formula derivative suits (8-K filed April 17, 2026). This removes a legal overhang that had been a background concern for the Nutrition segment.
• Shareholder Meeting / New Incentive Plan (April 27, 2026): Abbott shareholders approved a new 140 million share incentive plan and expanded the Board (8-K filed April 27, 2026). The new incentive plan signals management's confidence in long-term value creation and aligns executive compensation with shareholder outcomes.
• Whoop Strategic Investment (late March 2026): Abbott made a strategic investment in Whoop, a wearable health monitoring company, signaling continued interest in the consumer health and wearables market adjacent to its CGM franchise.
• Exact Sciences Integration Progress: CEO Robert Ford has been personally field-traveling with Cologuard reps and meeting with health ministers in Asia and Europe. Jake Orville named as new leader of the Cancer Diagnostics business, reporting directly to the CEO. Integration described as going "very well" with strong cultural compatibility.
• Analyst Price Target Resets: Multiple firms cut price targets post-Q1 earnings (Raymond James $130→$115; Mizuho $125→$115; UBS $158→$135; Bank of America $120→$102; Evercore ISI $120→$112). Baird initiated at Outperform with $121 PT. Average consensus PT ~$118.42, implying ~33% upside from current levels.
• CGM Regulatory Catalyst Pending: CMS proposed language on Type 2 non-insulin reimbursement coverage for CGM is expected; management explicitly excluded this from guidance, representing potential upside optionality. Dual analyte system approval also expected in H2 2026.
• International Cancer Screening Expansion: CEO met with health ministers in Asia and Europe who identified cancer screening as a top priority. International expansion of Cologuard is a stated priority and could be a significant long-term growth driver not yet reflected in consensus estimates.

8. Insider Transaction Activity (Since Q1 2026 Earnings)

Key Takeaway: Insider activity since Q1 2026 earnings is dominated by routine equity compensation grants (code A) to directors and executives, with no open-market purchases or sales by senior management. The one notable exception is CFO Philip Boudreau's spouse purchasing 2,200 shares on April 23, 2026 (one week after earnings), which could be interpreted as a modest positive signal at the post-earnings lows.

Source: Insider Transaction Data (SEC Form 4 filings). Transaction codes: A = equity grant/award; P = open-market purchase; F = tax withholding disposition (shares withheld to cover taxes on vesting, not a discretionary sale); I = indirect holding (profit sharing trust). No discretionary open-market sales by senior executives were recorded in the period.

Interpretation: The two open-market purchases — CFO Boudreau's spouse buying 2,200 shares at ~$91–92 on April 23 and Director Stratton buying 2,000 shares at ~$87 on May 7 — are modest in size but directionally positive signals. Both purchases occurred after the post-Q1 earnings selloff, suggesting insiders viewed the stock as attractively valued at those levels. The absence of any discretionary sales by senior management is also constructive.

Appendix: Key Risks & Considerations

• CGM Growth Deceleration Risk: If FreeStyle Libre fails to return to double-digit growth in Q2 (management's explicit guidance), it would be the third consecutive miss on the franchise and could trigger a more significant re-rating of the CGM growth story. DXCM's strong Q1 performance sets a high bar for market expectations.
• Exact Sciences Integration Execution: The $3B incremental FY2026 revenue target from Exact Sciences is a significant addition to the model. Any signs of integration friction, Cologuard growth deceleration, or reimbursement headwinds for cancer diagnostics could weigh on sentiment.
• Nutrition Recovery Pace: The Nutrition segment is expected to show improving growth over the course of 2026, but consensus Q2 Nutrition at $2.13B is still below the prior-year $2.21B. A slower-than-expected volume recovery would be a negative surprise.
• Tariff / FX Exposure: Abbott operates in 160+ countries with global manufacturing. Tariff escalation (as flagged by ISRG with 100 bps gross margin impact) and FX volatility are ongoing risks, though management guided for "relatively neutral" FX impact in Q2.
• Structural Heart Competitive Pressure: ABT's MitraClip faces competitive pressure in mitral, and the reclassification of LAA/Amulet into the EP segment may obscure underlying Structural Heart performance. EW's strong TAVR results are a positive market read-through, but ABT's execution in this segment has been inconsistent.
• Respiratory Season Optionality: Management explicitly excluded any respiratory season recovery from Q4 guidance. If respiratory testing picks up in Q2 (summer respiratory viruses), this would be incremental upside to Diagnostics estimates.
• CMS Reimbursement Catalyst: CMS proposed language on Type 2 non-insulin CGM reimbursement coverage is pending and not included in guidance. Approval would be a significant positive catalyst for FreeStyle Libre's U.S. growth trajectory.